9QI6

Structure of I105R BlaC from Mycobacterium tuberculosis bound to the trans-enamine adduct of clavulanic acid

Summary for 9QI6

• Entry DOI: 10.2210/pdb9qi6/pdb
• Descriptor: Beta-lactamase, ZINC ION, ACETATE ION, ... (7 entities in total)
• Functional Keywords: beta-lactamase, blac, clavulanic acid, hydrolase
• Biological source: Mycobacterium tuberculosis
• Total number of polymer chains: 2
• Total formula weight: 58044.61

Authors

Chikunova, A.,Radojkovic, M.,Ubbink, M. (deposition date: 2025-03-17, release date: 2025-06-11, Last modification date: 2025-07-23)

Primary citation

Radojkovic, M.,Chikunova, A.,Koene, S.F.,Timmer, M.,Natarajan, S.V.,Boyle, A.L.,Ubbink, M.
A glycine at position 105 leads to clavulanic acid and avibactam resistance in class A beta-lactamases.
J.Biol.Chem., 301:110347-110347, 2025

PubMed Abstract: β-Lactamase enzymes exhibit extraordinary adaptive potential, thus rendering many β-lactam drugs ineffective. The residue at Ambler position 105, also known as the gatekeeper residue, plays an important role in substrate recognition, but its implication in inhibition mechanisms is understudied and obscure. To inspect the relationship between inhibitor-resistant phenotypes and residues at this position, we performed site-saturation mutagenesis and extensive fitness profiling of five distinct class A β-lactamases using deep sequencing. We found that inhibitor resistance is readily detectable, with variants harboring Gly or Arg being the least susceptible to inhibitors. Mutation of Ile105 to Arg in the β-lactamase BlaC simultaneously enhances activity for carbenicillin and the ability to evade clavulanic acid inhibition. The Y105G substitution in two clinically important enzymes, CTX-M-14 and TEM-1, confers greatly reduced in vitro sensitivity to avibactam, which we attribute to elevated conformational flexibility of the inhibitor within the active site. The findings presented in this study underpin the gatekeeper residue as a possible mutational hotspot and might aid the design of novel β-lactamase inhibitors.

PubMed: 40484381
DOI: 10.1016/j.jbc.2025.110347

Experimental method

X-RAY DIFFRACTION (1.8 Å)